These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35112882)

  • 1. Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.
    Fordyce CB; Giugliano RP; Cannon CP; Roe MT; Sharma A; Page C; White JA; Lokhnygina Y; Braunwald E; Blazing MA
    J Am Heart Assoc; 2022 Feb; 11(4):e022733. PubMed ID: 35112882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
    Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
    Fanaroff AC; Roe MT; Clare RM; Lokhnygina Y; Navar AM; Giugliano RP; Wiviott SD; Tershakovec AM; Braunwald E; Blazing MA
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28923989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
    Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Kato ET; Cannon CP; Blazing MA; Bohula E; Guneri S; White JA; Murphy SA; Park JG; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
    Bach RG; Cannon CP; Giugliano RP; White JA; Lokhnygina Y; Bohula EA; Califf RM; Braunwald E; Blazing MA
    JAMA Cardiol; 2019 Sep; 4(9):846-854. PubMed ID: 31314050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
    Hess PL; Wojdyla DM; Al-Khatib SM; Lokhnygina Y; Wallentin L; Armstrong PW; Roe MT; Ohman EM; Harrington RA; Alexander JH; White HD; Van de Werf F; Piccini JP; Held C; Aylward PE; Moliterno DJ; Mahaffey KW; Tricoci P
    JAMA Cardiol; 2016 Apr; 1(1):73-9. PubMed ID: 27437658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
    Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
    JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database.
    Hui SK; Sharma A; Docherty K; McMurray JJV; Pitt B; Dickstein K; Pfeffer MA; Girerd N; Rossignol P; Ferreira JP; Zannad F
    Eur Heart J Acute Cardiovasc Care; 2021 Apr; 10(2):127-131. PubMed ID: 33620418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.
    Patel SM; Qamar A; Giugliano RP; Jarolim P; Marston NA; Park JG; Blazing MA; Cannon CP; Braunwald E; Morrow DA
    JAMA Cardiol; 2022 Dec; 7(12):1199-1206. PubMed ID: 36260325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
    Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
    J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
    Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
    Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Pokharel Y; Chinnakondepalli K; Vilain K; Wang K; Mark DB; Davies G; Blazing MA; Giugliano RP; Braunwald E; Cannon CP; Cohen DJ; Magnuson EA
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction.
    Koivunen M; Tynkkynen J; Oksala N; Eskola M; Hernesniemi J
    Am Heart J; 2023 Mar; 257():9-19. PubMed ID: 36384178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
    Eisen A; Ruff CT; Braunwald E; Nordio F; Corbalán R; Dalby A; Dorobantu M; Mercuri M; Lanz H; Rutman H; Wiviott SD; Antman EM; Giugliano RP
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27402235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
    Zelniker TA; Morrow DA; Scirica BM; Furtado JD; Guo J; Mozaffarian D; Sabatine MS; O'Donoghue ML
    J Am Heart Assoc; 2021 Apr; 10(8):e017401. PubMed ID: 33840228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.
    Kuch M; Janiszewski M; Mamcarz A; Cudnoch-Jedrzejewska A; Dłuzniewski M
    Med Sci Monit; 2009 Jun; 15(6):PH40-8. PubMed ID: 19478711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).
    Fox KA; Carruthers KF; Dunbar DR; Graham C; Manning JR; De Raedt H; Buysschaert I; Lambrechts D; Van de Werf F
    Eur Heart J; 2010 Nov; 31(22):2755-64. PubMed ID: 20805110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2014 Dec; 60(12):1095-101. PubMed ID: 25692840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
    Bohula EA; Morrow DA; Giugliano RP; Blazing MA; He P; Park JG; Murphy SA; White JA; Kesaniemi YA; Pedersen TR; Brady AJ; Mitchel Y; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2017 Feb; 69(8):911-921. PubMed ID: 28231942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.